Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Analysis of a profile of lipid metabolism genes in advanced non-small cell lung cancer.
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20619)
Author(s): Maria Merino, Lara Fernández, Ana Ramirez de Molina, Juan Moreno, Gonzalo Colmenarejo, Sandra Falagan, César Gómez, Miriam Lopez-Gomez, Francisco Zambrana, Ana M. Jimenez Gordo, Cristina Aguayo, Enrique Casado, Maria Sereno Moyano; Medical Oncology Department, Infanta Sofía University Hospital, Madrid, Spain; Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain; Molecular Oncology Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain; Biostatistics and Bioinformatics Unit, IMDEA-Food Institute, CEI UAM, CSIC, Madrid, Spain; Medical Oncology Department, Infanta Sofía University Hospital, San Sebastián De Los Reyes, Spain; Infanta Sofía University Hospital, San Sebastián De Los Reyes, Spain; Infanta Sofía Hospital, San Sebastián De Los Reyes, Spain
Background: Non- small cell lung cancer (NSCLC) is one of the tumors with the highest mortality rate. The underlying metabolic alterations involved in its carcinogenesis are becoming more interesting. According to this, the analysis of the dysregulation of genes involved in lipid metabolism (LM) is subject to a growing research. To evaluate a profile of genes involved in lipid metabolism in NSCLC, we analyzed the correlation of this gene expression profile with different clinical-pathological variables. Methods: We performed a retrospective analysis of 22 genes related to LM in samples of NSCLC as well as clinical-pathological features. Advanced NSCLC patients enrolled from 2008 through 2015 were included. Clinical and pathological data were collected from medical reports. This study was approved in our ethical committee and all patients signed the consent inform. Samples were deparaffinated and RNA was extracted using RNeasy FFPE Kit (Qiagen Gmbh, Germany). A Taq-Man Low Density Array (Applied Biosystems) was specifically designed and gene-expression assays were performed in a HT-7900 Fast Real time PCR. RT-StatMiner software (Integromics Inc., Madison, USA) was used to detect and determine the quality control and differential expression analyses of data. Quantification of gene expression was calculated with the 2–ΔCt method. The Kaplan–Meier method was used for survival probabilities, and the log-rank test was to test differences between subgroups. Results: Ninety patients with advanced NSCLC were included. Median age was 64, 68/90 (75%) were male; 46/90 (51%) were ECOG 1; 68/90 (75%) adenocarcinoma vs 22/90 (24%) squamous; 47/90 (52%) smokers and 34% former smokers; metformine intake was presented in 9/90 (10%) and statins 24/90 (27%). In retrospective RT-PCR analysis including a lipid metabolism gene profile of 22 genes, we obtained an overexpression of 2 genes (an Acyl-CoA sintetase and a adipocine encoding gene). They were significantly correlated with overall poor survival in the multivariate analysis (table). These results were confirmed in an in silico validation using 994 NSCLC patients from TCGA study. Conclusions: This is the first study demonstrating a significant relation with a poor survival between a metabolic lipid gene profile expression and survival in advanced non- small cell lung cancer
|Acyl-CoA sintetase encoding gene||0.04||2.93 (1.5-5.73)||0.0005||0.011|
|Adipocine encoding gene||0.02||3.23 (1.61-6.49)||0.0002||0.0044|
|Acyl-CoA sintetase encoding gene (TCGA validation)||0.00088|